Since the discovery of penicillin in 1928, antibiotics have saved countless lives. However, as Alexander Fleming warned during a lecture in 1945, the misuse and overuse of antibiotics have led to the development of bacteria that are resistant to one or more classes of antibiotics. Global organizations including the Infectious Disease Society of America, Health Canada, the UK Department of Health, and the UN General Assembly concur that the development of new antibiotics is a crucial element in the effort to address the serious and growing threat of antibiotic resistance.


Fedora is committed to applying the company’s 30-years of cumulative experience in anti-infectives research to the development of novel antibiotics targeting Gram-negative and Gram-positive microbes. Among those areas of interest are the ESKAPE pathogens (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species), which the World Health Organization has identified as the most critical unmet needs. 

11629 – 105 Avenue, Edmonton, AB T5H 0L9  |   780-757-5401

© 2017 Fedora Pharmaceuticals Inc. 

  • Facebook - Black Circle
  • LinkedIn - Black Circle